Payment overview · 2025
General Payments
$289.23
14 reported records · 11 companies
Healthcare provider profile · identity verified
Prixit Sharma, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AVON PARK, FL · NPI 1003803156
Verified facts
What the public records show
CMS Open Payments records show Prixit Sharma, M.D. received $289.23 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.28 | 13.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.97 | 11.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.18 | 11.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29.23 | 10.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.36 | 9.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.90 | 8.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.59 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.10 | 7.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.07 | 6.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.42 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.13 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $289.23 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
131 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 39 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1460 | 427 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1194 | 354 |
| Levothyroxine Sodium | Levothyroxine Sodium | 993 | 268 |
| Alprazolam | Alprazolam | 864 | 177 |
| Pantoprazole Sodium | Pantoprazole Sodium | 809 | 256 |
| Losartan Potassium | Losartan Potassium | 641 | 187 |
| Omeprazole | Omeprazole | 628 | 182 |
| Lisinopril | Lisinopril | 564 | 163 |
| Gabapentin | Gabapentin | 563 | 165 |
| Methylprednisolone | Methylprednisolone | 552 | 426 |
| Metformin Hcl | Metformin Hcl | 533 | 163 |
| Metoprolol Tartrate | Metoprolol Tartrate | 502 | 151 |
| Azithromycin | Azithromycin | 500 | 390 |
| Tramadol Hcl | Tramadol Hcl | 454 | 102 |
| Clopidogrel | Clopidogrel Bisulfate | 434 | 129 |
| Carvedilol | Carvedilol | 429 | 128 |
| Tamsulosin Hcl | Tamsulosin Hcl | 422 | 135 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 411 | 95 |
| Furosemide | Furosemide | 394 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 117 |
| Simvastatin | Simvastatin | 372 | 102 |
| Glimepiride | Glimepiride | 341 | 99 |
| Allopurinol | Allopurinol | 322 | 91 |
| Lorazepam | Lorazepam | 320 | 56 |
| Meloxicam | Meloxicam | 319 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 309 | 97 |
| Famotidine | Famotidine | 306 | 105 |
| Atenolol | Atenolol | 302 | 78 |
| Montelukast Sodium | Montelukast Sodium | 279 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 274 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 77 |
| Finasteride | Finasteride | 268 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 91 |
| Eliquis | Apixaban | 239 | 70 |
| Fluoxetine Hcl | Fluoxetine Hcl | 230 | 51 |
| Potassium Chloride | Potassium Chloride | 221 | 75 |
| Sertraline Hcl | Sertraline Hcl | 199 | 56 |
| Trazodone Hcl | Trazodone Hcl | 198 | 58 |
| Metformin Hcl Er | Metformin Hcl | 193 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 189 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 177 | 51 |
| Clonidine Hcl | Clonidine Hcl | 176 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 174 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 49 |
| Jardiance | Empagliflozin | 161 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 158 | 76 |
| Ozempic | Semaglutide | 156 | 39 |
| Mounjaro | Tirzepatide | 155 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 149 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 139 | 42 |
| Lovastatin | Lovastatin | 137 | 37 |
| Prednisone | Prednisone | 137 | 73 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 131 | 30 |
| Januvia | Sitagliptin Phosphate | 130 | 34 |
| Clonazepam | Clonazepam | 128 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 117 | 34 |
| Celecoxib | Celecoxib | 111 | 39 |
| Nifedipine Er | Nifedipine | 106 | 29 |
| Spironolactone | Spironolactone | 105 | 34 |
| Temazepam | Temazepam | 103 | 20 |
| Warfarin Sodium | Warfarin Sodium | 103 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 94 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 77 |
| Glipizide | Glipizide | 99 | 32 |
| Mirtazapine | Mirtazapine | 94 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 26 |
| Synthroid | Levothyroxine Sodium | 80 | 24 |
| Pregabalin | Pregabalin | 79 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 22 |
| Diazepam | Diazepam | 73 | 21 |
| Donepezil Hcl | Donepezil Hcl | 73 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 27 |
| Ezetimibe | Ezetimibe | 71 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 19 |
| Baclofen | Baclofen | 67 | 21 |
| Cefdinir | Cefdinir | 67 | 60 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 19 |
| Alendronate Sodium | Alendronate Sodium | 63 | 17 |
| Levetiracetam | Levetiracetam | 60 | 22 |
| Memantine Hcl | Memantine Hcl | 59 | 13 |
| Irbesartan | Irbesartan | 58 | 15 |
| Propranolol Hcl | Propranolol Hcl | 58 | 18 |
| Ibuprofen | Ibuprofen | 57 | 16 |
| Labetalol Hcl | Labetalol Hcl | 57 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 57 | 40 |
| Doxepin Hcl | Doxepin Hcl | 56 | suppressed |
| Fenofibrate | Fenofibrate | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 55 | suppressed |
| Fluconazole | Fluconazole | 54 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 32 |
| Enalapril Maleate | Enalapril Maleate | 52 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 16 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Bumetanide | Bumetanide | 48 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Levofloxacin | Levofloxacin | 47 | 38 |
| Primidone | Primidone | 47 | 13 |
| Benazepril Hcl | Benazepril Hcl | 45 | 14 |
| Naproxen | Naproxen | 45 | 30 |
| Topiramate | Topiramate | 45 | 13 |
| Indomethacin | Indomethacin | 44 | 14 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 43 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 15 |
| Valacyclovir | Valacyclovir Hcl | 41 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 17 |
| Xarelto | Rivaroxaban | 40 | 12 |
| Chlorthalidone | Chlorthalidone | 39 | 12 |
| Sotalol | Sotalol Hcl | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 32 |
| Digoxin | Digoxin | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 12 |
| Mupirocin | Mupirocin | 36 | 33 |
| Entresto | Sacubitril/Valsartan | 35 | 12 |
| Nitroglycerin | Nitroglycerin | 35 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 19 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 13 |
| Torsemide | Torsemide | 29 | 15 |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 26 | 11 |
| Estradiol | Estradiol | 26 | 12 |
| Nystatin | Nystatin | 26 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 23 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | 11 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 11 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 19 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $289.23 · 14 records | Lilly USA, LLC | AUSTEDO XR, Cologuard Collection Kit, Dexcom G6 Transmitter, Flector, KISUNLA, Korlym, Licart, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, TRELEGY ELLIPTA, Tirosint, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error